Inhibrx Biosciences, Inc. Sample Contracts
WARRANT TO PURCHASE COMMON STOCK INHIBRX BIOSCIENCES, INC.Warrant Agreement • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [·] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from INHIBRX BIOSCIENCES, INC., a Delaware corporation (the “Company”), up to [·] shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Standard Contracts
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [•], by and between INHIBRX BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [•] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
Re: Employment Agreement Assignment and AssumptionEmployment Agreement Assignment and Assumption • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances)
In connection with the spin-off of Inhibrx Biosciences, Inc. (“Inhibrx Biosciences”), Inhibrx, Inc. (“Inhibrx”) hereby assigns its respective rights and obligations under each of the Second Amended and Restated Executive Employment Agreement, by and between you and Inhibrx, effective as of January 1, 2023 (your “Employment Agreement”), the compensation update letter, by and between you and Inhibrx, dated as of January 4, 2024 (your “Compensation Letter”) and the Proprietary Information and Inventions Agreement, by and between you and Inhibrx, dated as of October 1, 2018 (your “PIIA”) to Inhibrx Biosciences, and Inhibrx Biosciences accepts and assumes such rights and obligations, effective as of the Distribution Date (as defined in the Separation and Distribution Agreement by and among Inhibrx Biosciences, Inhibrx and others dated as of January 22, 2024, as in effect from time to time) (collectively, the “Assignment”). The Distribution Date is currently anticipated to occur on or about
EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (this “Agreement”) is effective as of May 30, 2024 (the “Effective Date”) by and between Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), and Brendan Eckelman (“Employee”). The Company and Employee are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 30th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 29, 2024, is made by and among Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), and the Holders listed on Schedule 1 hereto (individually, a “Holder” and collectively, the “Holders”).
TRANSITION SERVICES AGREEMENT BETWEEN INHIBRX BIOSCIENCES, INC. AND INHIBRX, INC. DATED MAY 29, 2024Transition Services Agreement • May 30th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This TRANSITION SERVICES AGREEMENT, dated May 29, 2024 (as amended, modified or supplemented from time to time in accordance with its terms, this “Agreement”), is made and entered into by and between Inhibrx, Inc., a Delaware corporation (“RemainCo”), and Inhibrx Biosciences, Inc., a Delaware corporation (“SpinCo”). Unless otherwise defined herein, all capitalized terms used herein shall have the same meanings as in the Separation Agreement (as defined below).
ContractWarrant Agreement • January 13th, 2025 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 13th, 2025 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of January 13, 2025 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFCF II”) and OXFORD FINANCE CREDIT FUND III LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFCF III”) (each a “Lender” and collectively, the “Lenders”), and INHIBRX BIOSCIENCES, INC., a Delaware corporation with